Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TLX vs SYRE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TLX Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 6–3 Matrix Metrics)

TLX Overall Winner 6-Pillar Tally: TLX 5 – 0 SYRE (1 Tie) Matrix Metrics: TLX 6 – 3 SYRE

As of Nov 16, 2026, Telix Pharmaceuticals Limited (TLX) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TLX carries a Unified Composite Score of 46.4/100 (HOLD) at $8.98 (N/M Forward P/E, 6.2% operating margin), whereas SYRE carries 44.4/100 (HOLD) at $99.97 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: TLX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile SYRE trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TLX vs SYRE
TLX NASDAQ Head-to-Head Winner
Telix Pharmaceuticals Limited American Depositary Shares
Pharmaceutical Preparations
$8.98
-2.65% 1D
Market Cap $3.2B
TTM Revenue $891M
Forward P/E N/M
Beta / 30D Vol 0.84β · 62% Vol
Unified Composite Score
46.4 / 100 HOLD
Tech 64.0 Fund 62.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.7%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $9.46 · SMA50: $10.61
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.75β · 59% Vol
Unified Composite Score
44.4 / 100 HOLD
Tech 31.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.5 · SMA20: $98.78 · SMA50: $91.70

6-Pillar Scorecard Institutional Category Breakdown (TLX 5 – 0 SYRE)

Columns: Metric · TLX · SYRE
1. Valuation Multiples TLX
Forward P/E N/M N/M
Trailing P/E 93.6x N/M
PEG Ratio N/M N/M
EV / Revenue 3.6x N/M
2. Growth & Scale TLX
Revenue Growth (YoY) +22.3% +0.0%
Earnings Growth (YoY) +0.0% -99.7%
TTM Revenue (USD) $891M N/A
Market Cap $3.2B $9.8B
3. Profitability & Quality TLX
Gross Margin 47.6% N/A
Operating Margin 6.2% 0.0%
Net Profit Margin 3.8% 0.0%
Return on Equity (ROE) 7.4% -35.0%
4. Balance Sheet & Cash Flow TLX
Cash Generation (TTM) $70M EBITDA N/A
Cash Flow Margin 7.8% EBITDA Mgn N/A
Net Cash / Leverage $1.44 Book/Sh · 7.4% ROE $10.06 Book/Sh · -35.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 87.9% (10th %ile)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat TLX
OpEx & R&D Intensity 41.4% of Rev ($369M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TLX (6) vs SYRE (3)
Institutional Metric TLX SYRE Criterion Row Edge
Market Capitalization
Scale
$3.2B $9.8B Larger Scale SYRE
Trailing P/E Ratio
Valuation
93.6x N/M Lower Multiple TLX
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+22.3% +0.0% Higher Growth TLX
Operating Margin (TTM)
Profitability
6.2% 0.0% Higher Margin TLX
Net Profit Margin
Profitability
3.8% 0.0% Higher Margin TLX
Return on Equity (ROE)
Capital Efficiency
7.4% -35.0% Higher ROE TLX
52-Week Range Position
Momentum
40% ($6–$13) 88% ($22–$111) Stronger Trend SYRE
Beta / 30D Volatility
Risk Regime
0.84β · 62% Vol 1.75β · 59% Vol Lower Realized Risk SYRE
Unified Institutional Score
Composite Signal
46.4 / 100 (HOLD) 44.4 / 100 (HOLD) Higher Composite TLX
Trailing 12M Revenue (USD)
Operating Scale
$891M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
47.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$70M EBITDA ($1.44 Book/Sh · 7.4% ROE) N/A ($10.06 Book/Sh · -35.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYRE +41.06 pp
TLX: -15.95% · SYRE: +25.11%
3M Horizon SYRE +17.08 pp
TLX: -24.37% · SYRE: -7.29%
6M Horizon SYRE +55.24 pp
TLX: -12.6% · SYRE: +42.64%
1Y Horizon SYRE +347.26 pp
TLX: -5.52% · SYRE: +341.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TLX vs SYRE. Trailing 12-month operating profitability (TLX 6.2% vs SYRE 0.0%) and valuation multiples (TLX N/M vs SYRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$891M
Gross Margin47.6%
Op. Margin6.2%
ROE / Fwd P/E7.4% · N/M
SYRE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-35.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TLX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SYRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SYRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TLX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.2B market capitalization and 6.2% operating margin.
OpEx & R&D Reinvestment 41.4% of Rev ($369M)
90D Engineering Disclosures 0 Published
SYRE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TLX vs SYRE Key Questions & Quantitative Answers

As of Nov 16, 2026, Telix Pharmaceuticals Limited (TLX) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TLX carries a Unified Composite Score of 46.4/100 (HOLD) at $8.98 (N/M Forward P/E, 6.2% operating margin), whereas SYRE carries 44.4/100 (HOLD) at $99.97 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: TLX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile SYRE trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TLX leads the Growth & Scale pillar: TLX posts +22.3% YoY revenue growth and +0.0% YoY earnings growth on $891M TTM revenue (47.6% gross margin, 6.2% operating margin), compared with SYRE at +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, TLX generates $891M in USD-normalized revenue versus N/A for SYRE. In operating R&D and SG&A reinvestment, TLX deploys 41.4% of Rev ($369M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SYRE.

TLX screens cheaper on headline valuation multiples. TLX trades at N/M Forward P/E, 93.6x Trailing P/E, N/M PEG, and 3.6x EV/Revenue (7.8% EBITDA margin), whereas SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TLX (7.4% ROE) versus SYRE (-35.0% ROE) capital efficiency.

In options market volatility and institutional positioning, TLX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.84β · 62% Vol realized risk). By comparison, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Telix Pharmaceuticals Limited American Depositary Shares (TLX) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.